Every Form 4 that Gyre Therapeutics, Inc. (GYRE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GYRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GYRE filings page.
Gyre Therapeutics director Claire Weston received a grant of stock options to purchase 40,000 shares of common stock at an exercise price of $6.11 per share. The options vest in 36 equal monthly installments through August 3, 2029 and expire on August 3, 2036, leaving her with options on 40,000 shares.
Gyre Therapeutics director Kirkby Maxwell received a grant of stock options covering 40,000 shares of common stock on August 3, 2026. The options have a $6.1100 exercise price, expire on August 3, 2036, and vest in 36 equal monthly installments through August 3, 2029, subject to continued service.
Gyre Therapeutics director Carmichael Gordon received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share, expire on June 10, 2036, and will vest in 12 equal monthly installments through June 10, 2027, contingent on continued service.
GYRE THERAPEUTICS, INC. director David M. Epstein received a grant of stock options to acquire 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036.
The award was made as a compensation-related grant, with no cash purchase by the insider at grant. According to the terms, the options will vest in 12 equal monthly installments through June 10, 2027, so long as Epstein continues to provide service to the company through each vesting date.
GYRE THERAPEUTICS, INC. director Dan Weng received a stock option grant covering 40,000 shares of common stock. The option has an exercise price of $5.95 per share and expires on June 10, 2036.
The award vests in 12 equal monthly installments through June 10, 2027, conditioned on continued service. After this grant, Weng holds stock options for 40,000 underlying shares directly, reflecting routine equity-based compensation rather than an open-market transaction.
GYRE THERAPEUTICS, INC. director Renate Parry received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036. According to the disclosure, the award vests in 12 equal monthly installments through June 10, 2027, contingent on Parry’s continued service to the company. This is a compensation-related acquisition, with no open‑market buying or selling reported in this filing.
GYRE THERAPEUTICS, INC. director Zhang Ping received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share, expire on June 10, 2036, and vest in 12 equal monthly installments through June 10, 2027 as long as service continues.
Gyre Therapeutics director Rodney L. Nussbaum received a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $5.95 per share, gives him the right to buy Gyre Therapeutics stock at that price until June 10, 2036.
The award was reported as a compensation-related grant, not an open-market purchase or sale. The option will vest in 12 equal monthly installments through June 10, 2027, subject to his continued service with the company. After this grant, he holds options for 40,000 underlying shares directly.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a series of option exercises paired with open-market sales of common stock. On June 9, 10, and 18, he exercised stock options at $0.75 per share to acquire a total of 11,000 shares of common stock, then sold 11,000 shares in open-market transactions at prices reported around $6.15–$6.35 per share. A footnote states some sales were reported as a weighted average with individual trades between $6.20 and $6.30 per share. After these transactions, Ye directly holds 700,000 shares of Gyre Therapeutics common stock.
GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported a same‑day option exercise and share sale. He exercised options to acquire 2,800 shares of common stock at an exercise price of $0.75 per share, then sold 2,800 shares in an open‑market transaction at a weighted average price of $6.17 per share.
After these transactions, Ye directly holds 700,000 shares of common stock. The exercised options covered 2,800 shares of common stock originally granted as a stock option (right to buy) that was fully vested.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported an exercise-and-sell sequence in company stock. On June 9 and 10, 2026, he sold a total of 20,918 shares of common stock in open-market transactions at reported prices of $6.14 and $6.21 per share, with actual sales executed across price ranges detailed in the footnotes.
On the same dates, he exercised stock options to acquire the same total of 20,918 shares of common stock at an exercise price of $0.75 per share. Following these transactions, he directly held 700,000 shares of common stock. The options exercised were reported as vested in full, and no remaining derivative positions are listed in this filing.
GYRE THERAPEUTICS, INC. reported a Form 4 showing that GC and Corporate Secretary Joshua Benjamin Bergmann received a grant of stock options to acquire 50,000 shares of common stock at an exercise price of $6.05 per share. These options expire on June 8, 2036. According to the vesting terms, 25% of the grant will vest on June 8, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to continued service. After this grant, Bergmann holds 50,000 derivative securities directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
GYRE THERAPEUTICS, INC. reported that Chief Executive Officer Luo Ying received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $6.05 per share and expire on June 8, 2036.
According to the grant terms, 25% of the options will vest on June 8, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Luo Ying’s continued service. Following this award, the filing shows 120,000 derivative securities held directly.
GYRE Therapeutics Chief Operating Officer Ye Weiguo reported an exercise-and-sell sequence in company stock. On June 4, 2026 and June 5, 2026, he exercised stock options to acquire a total of 34,976 shares of common stock at an exercise price of $0.75 per share and then sold the same number of shares in open-market transactions.
The 19,575-share sale on June 4 occurred at a weighted average price of $6.13 per share in trades ranging from $6.05 to $6.30, while the 15,401-share sale on June 5 was at a weighted average price of $6.40 per share in trades ranging from $6.15 to $6.60. After these transactions, Weiguo directly holds 700,000 shares of GYRE common stock.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported option exercises paired with open-market sales of common stock. On May 22 and May 26, he exercised stock options to acquire a total of 7,500 shares of common stock at an exercise price of $0.75 per share and sold 7,500 shares in open-market transactions.
The reported sale prices include $6.0800 per share for 3,500 shares and a weighted average price of $6.1001 per share for 4,000 shares, with individual trades ranging from $6.04 to $6.1051. Following these transactions, Ye’s directly held common stock position is reported at approximately 700,000 shares, indicating the activity mainly reflects option-related liquidity rather than a large change in overall ownership.
GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported option exercises and related share sales. He exercised stock options covering 22,220 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions.
The common stock sales on May 20 and May 21, 2026 were executed at a weighted average price of $6.15 per share, with actual sale prices ranging from about $6.05 to $6.29 according to the footnotes. After these transactions, Ye directly owns 700,000 shares of GYRE common stock.
GYRE Therapeutics director Zhang Ping reported a cancellation of stock options previously granted by the company. A stock option covering 250,000 shares of common stock with a $10.18 exercise price and a May 27, 2035 expiration was disposed of back to the issuer.
According to the disclosure, the option was canceled by mutual agreement, and the company will provide consideration whose form and amount it will determine, but this consideration will not have economic value. The canceled grant would have begun vesting on May 27, 2026, with monthly vesting over three additional years, and no shares remain from this option after the transaction.
GYRE Therapeutics Chief Operating Officer Ye Weiguo reported a small exercise-and-sell sequence in common stock. On May 18–19, he exercised stock options covering 9,320 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions at weighted average prices around $6.37 per share, within disclosed price ranges. Following these transactions, he directly holds 700,000 shares of common stock.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a small exercise-and-sell pattern over two days. On May 14 and 15, 2026, he exercised stock options to acquire a total of 28,680 shares of common stock at $0.75 per share and sold the same number of shares in open-market transactions, at weighted average prices of $6.91 and $6.65, respectively, across multiple trades.
After these transactions, Ye directly owns 700,000 shares of common stock. All options involved were fully vested, and the sales were executed across price ranges disclosed through weighted-average pricing footnotes.
GYRE Therapeutics, Inc. Chief Executive Officer Luo Ying reported indirect open-market sales of company common stock held by a spouse. On May 5–6, 2026, a total of 10,315 shares of common stock were sold in two transactions at weighted average prices of $8.01 and $8.04 per share. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025, indicating they were pre-arranged. Following these transactions, indirect holdings reported as owned through the spouse totaled 2,565,226 shares of common stock.
GYRE THERAPEUTICS, INC. disclosed that GNI Group Ltd. and GNI USA, Inc., each a ten percent owner, received Series B Preferred Stock in connection with Gyre’s merger with Cullgen Inc., which became a wholly-owned subsidiary effective May 4, 2026.
GNI Group Ltd. holds 2,143,706 shares of Series B Preferred Stock, representing 10,718,530 underlying common shares, and GNI USA holds 458,120 shares, representing 2,290,600 underlying common shares. Each preferred share will be convertible into five common shares following stockholder approval, subject to a Beneficial Ownership Limitation, and the Series B Preferred Stock has no expiration date.
Eastling Thomas Wilson reported acquisition or exercise transactions in this Form 4 filing.
GYRE THERAPEUTICS, INC. reported that Chief Financial Officer Thomas Wilson received multiple stock option awards on May 4, 2026. These derivative transactions are all coded as grants and reflect compensation, not open‑market buying or selling of common shares.
The awards include options to purchase 92,683 shares of common stock at $5.98 per share expiring on November 12, 2034, and other options covering 95,060 shares at $2.34, 47,530 shares at $0.93, and additional grants at $2.00 and $0.32 per share with expirations between 2028 and 2031. One option for 33,271 shares at $0.32 is held indirectly through his spouse, and one option is already fully vested, while another 92,683‑share grant vests over time starting November 13, 2025.
Gyre Therapeutics director Zhang Ping reported receiving a new stock option grant for 100,000 shares of the company’s common stock. The option has an exercise price of $7.31 per share and was granted on January 7, 2026. According to the filing, 25% of the option will vest on January 7, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, conditioned on Zhang’s continued service to the company. After this grant, Zhang beneficially owns 100,000 derivative securities (stock options) directly.
Gyre Therapeutics, Inc. disclosed that its Chief Financial Officer, Ruoyu Chen, received a grant of stock options on January 7, 2026. The award is an option to purchase 50,000 shares of Gyre’s common stock at an exercise price of $7.31 per share.
According to the terms, 25% of the option will vest on January 7, 2027, with the remaining portion vesting in equal monthly installments over the following three years, subject to Chen’s continued service with the company through each vesting date. After this grant, Chen holds 50,000 stock options directly.